BioWorld

Aug. 27, 2008

Indevus Closes $105M Note Deal Backed by Sanctura Royalties

Indevus Pharmaceuticals Inc. joined the ranks of biotechs leveraging royalty streams to access nondilutive financing. (BioWorld Today) Read More

QLT Anticipates Excess of Cash Following Atrigel, Other Deals

Restarted Pharmalink Generates Promising Phase III Data in PPS

Novosom In-Licenses Antisense CD40 Inhibitors from Isis Pharma

Other News To Note

Clinic Roundup

Today's news in brief

BioWorld

BioWorld briefs for June 9, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for June 9, 2026

3D rendering of β2-Adrenergic receptor GPCR protein molecule embedded in lipid bilayer membrane.

Skape Bio unlocks GPCR targets with de novo-designed miniproteins

BioWorld

Modulating G protein-coupled receptors (GPCRs) is one of the major challenges in biomedicine. These are flexible proteins with small, deep binding pockets. The...

Antares Therapeutics divulges new CDK2/cyclin E1 inhibitors

BioWorld Science

Antares Therapeutics Inc. has reported new CDK2/cyclin E1 inhibitors potentially useful for the treatment of cancer.

Empire Discovery Institute, Univ. of Rochester identify IRAK inhibitors

BioWorld Science

Empire Discovery Institute and the University of Rochester have discovered new interleukin-1 receptor-associated kinase 1 (IRAK-1) and/or IRAK-4 inhibitors...